Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.
For the first time in 3 years, the IDWeek conference was held in-person.
Contagion was there, covering the latest developments in infectious disease research. Here's a roundup of some of our favorite interviews, featuring a range of the most significant topics covered at this year's conference.
What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.
After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.
A late-breaking IDWeek 2022 study found high seroprotection was achieved among people living with HIV after receiving 3 doses of a hepatitis B vaccine.
Amanda Jezek, senior vice president of public policy and government relations at IDSA, feels Congress is making significant progress toward antimicrobial resistance legislation.
During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.